Europe High Intensity Focused Ultrasound (HIFU) Market Report by Imaging Technology, Application, End User, Countries and Companies Analysis 2026-2034

Europe High-Intensity Focused Ultrasound Market Size & Forecast 2026-2034

Europe High Intensity Focused Ultrasound (HIFU) Market is expected to witness steady growth over the forecast period. It is projected to increase from US$ 37.57 Billion in 2025 to US$ 70.3 Billion in 2034, registering a Compound Annual Growth Rate (CAGR) of 7.21% from 2026-2034. Growth is driven by rising adoption of non-invasive therapeutic procedures, increasing prevalence of cancer and uterine fibroids, and advancements in medical imaging technologies.

Europe High Intensity Focused Ultrasound Market Overview

High Intensity Focused Ultrasound (HIFU) is a non-invasive medical technology that uses precisely focused ultrasound waves to generate heat and destroy targeted tissue without damaging surrounding healthy structures. It is widely used as an alternative to surgery for treating tumors and other medical conditions. In Europe, HIFU has gained strong popularity due to increasing demand for minimally invasive procedures that offer faster recovery, reduced hospital stays, and lower risk of complications.

HIFU is commonly used in oncology for treating prostate, liver, kidney, and breast cancers. It is also used in gynecology for managing uterine fibroids and adenomyosis, and in aesthetic medicine for skin tightening and facial lifting. The technology is especially valued in European healthcare systems that emphasize patient safety, cost-effectiveness, and advanced treatment methods.

The growing aging population, rising cancer incidence, and continuous technological advancements in imaging and ultrasound guidance have further strengthened adoption across Europe. Countries such as Germany, France, and the UK are leading users due to strong healthcare infrastructure and supportive regulatory approvals. As awareness increases, HIFU is becoming an increasingly preferred therapeutic option across both public and private healthcare sectors in Europe.

Cancer Incidence Crude Rates in Europe, 1995 vs. 2022

Estimated number of cancer incidence cases per 100,000 inhabitants (crude rates) in European countries

Country/Region 1995 (Cases per 100,000) 2022 (Cases per 100,000)

EU-27 400 620

Belgium (BE) 260 450

Bulgaria (BG) 300 470

Austria (AT) 450 520

Cyprus (CY) 310 530

Malta (MT) 310 540

Romania (RO) 340 550

Ireland (IE) 320 550

Poland (PL) 320 550

Slovakia (SK) 330 560

Croatia (HR) 440 570

Estonia (EE) 310 580

Czechia (CZ) 420 590

Latvia (LV) 350 600

Slovenia (SI) 450 600

Luxembourg (LU) 450 610

Finland (FI) 400 630

France (FR) 430 650

Portugal (PT) 420 650

Hungary (HU) 410 650

Sweden (SE) 350 660

Netherlands (NL) 420 700

Norway (NO) 430 710

Denmark (DK) 460 760

Source: Comparator Report on Cancer in Europe 2025

High-Intensity Focused Ultrasound Product launches in Europe

Year Product Company European Launch / Milestone

2024 System ONE-M TOOsonix Received CE Mark for treatment of non-melanoma skin cancers and other dermatologic lesions in Europe.

2024 System ONE-M TOOsonix Commercial rollout across European dermatology clinics following CE approval.

2025 Focal One Robotic HIFU System EDAP TMS CE-mark expansion for treatment of posterior deep infiltrating endometriosis in Europe.

2025 Focal One EDAP TMS European commercialization of the new endometriosis indication.

2025 Sonalleve MR-HIFU Profound Medical Expanded European deployment for bone and musculoskeletal applications following prior CE approvals.

2025 TULSA-PRO Profound Medical Additional European market expansion in CE-mark countries for MRI-guided ultrasound prostate therapy.

2025 Image-Guided Dermatologic HIFU Platform TOOsonix Broader European launch into skin oncology and dermatology centers.

2026 System ONE-M (expanded applications) TOOsonix Continued European rollout for additional dermatologic indications.

2026 Sonalleve MR-HIFU Profound Medical Adoption growth across European focused-ultrasound centers.

2026 Next-generation clinical HIFU systems (multiple vendors) Various manufacturers New deployments and upgrades at European focused-ultrasound centers reported during 2026 industry meetings.

Growth Driver of the Europe High Intensity Focused Ultrasound Market

Rising Demand for Minimally Invasive Treatments

The Europe High Intensity Focused Ultrasound (HIFU) Market is strongly driven by the increasing preference for minimally invasive and non-surgical treatment options. Patients and healthcare providers across Europe are shifting toward procedures that reduce hospital stays, lower infection risks, and ensure faster recovery times. HIFU fits these requirements perfectly as it offers precise tissue ablation without incisions or radiation exposure. This is especially important in oncology and gynecology, where patients seek safer alternatives to traditional surgery. European healthcare systems, known for cost-efficiency and advanced medical care, are actively adopting technologies that reduce long-term treatment expenses. Additionally, improved patient awareness and trust in non-invasive technologies are accelerating demand. Hospitals and specialty clinics are investing in HIFU systems to enhance treatment portfolios and attract patients seeking advanced care options. As healthcare modernization continues across Europe, minimally invasive solutions like HIFU are expected to remain a key growth driver in the market. February 2022: Medtronic plc and OLV Hospital Aalst announced that the first clinical procedure in Europe had been performed with the Hugo robotic-assisted surgery (RAS) system.

Rising Prevalence of Cancer and Chronic Diseases

The growing incidence of cancer and chronic diseases across Europe is another major factor driving the HIFU market. Prostate cancer, liver tumors, breast cancer, and uterine fibroids are increasingly common, particularly among the aging population. HIFU offers a targeted and effective treatment option for these conditions, making it highly relevant in modern healthcare settings. As Europe experiences a demographic shift toward an older population, the demand for advanced therapeutic technologies continues to rise. HIFU is especially beneficial for patients who are not suitable candidates for surgery due to age or comorbidities. It provides a non-invasive alternative with fewer side effects and quicker recovery. Governments and healthcare organizations across Europe are also focusing on early diagnosis and advanced treatment options, further supporting adoption. With rising disease burden and increasing healthcare needs, HIFU is becoming an important part of treatment strategies across oncology and other therapeutic areas in Europe. In 2020, GLOBOCAN projected 325,000 new cases of colon cancer and 182,000 cases of rectum cancer in Europe, with forecasts of 414,000 and 223,000 cases by 2040. The increased use of minimally invasive procedures, including laparoscopic and robotic surgery, has emerged as the preferred method of treatment for colon cancer, most likely to propel market growth.

Technological Advancements in Imaging and Ultrasound Systems

Technological innovation in imaging and ultrasound systems is significantly boosting the Europe HIFU market. Advanced real-time imaging technologies such as MRI-guided and ultrasound-guided HIFU systems have improved treatment accuracy, safety, and efficiency. These innovations allow physicians to precisely target diseased tissues while minimizing damage to surrounding healthy areas. Continuous improvements in device design, energy delivery systems, and software integration have expanded the clinical applications of HIFU across multiple specialties. European medical technology companies and research institutions are actively investing in R&D to enhance treatment outcomes and expand indications. Integration of artificial intelligence and robotic-assisted systems is further improving procedural precision and workflow efficiency. These advancements are making HIFU more accessible and reliable for hospitals and clinics. As technology continues to evolve, it is expected to drive wider adoption of HIFU across Europe, strengthening its position as a preferred non-invasive treatment option in modern healthcare systems. May 2025, Classys has secured European Union approval for its anti-aging device Volnewmer, becoming the first company to receive CE medical device regulation (MDR) certification for a radiofrequency-based aesthetic system.

Challenges of the Europe High Intensity Focused Ultrasound Market

High Cost of HIFU Equipment and Procedures

One of the key challenges in the Europe HIFU market is the high cost associated with equipment and treatment procedures. HIFU systems require advanced imaging integration, precision engineering, and sophisticated software, making them expensive to purchase and maintain. Hospitals and healthcare facilities must invest significant capital to install and operate these systems, which limits adoption, especially in smaller clinics and public hospitals with budget constraints. Additionally, the cost of individual HIFU procedures can be higher than conventional treatments in some cases, depending on insurance coverage and healthcare reimbursement policies. Training medical professionals to operate HIFU devices also adds to overall expenses. In several European countries, limited reimbursement frameworks for non-invasive treatments further restrict patient access. As a result, despite its clinical advantages, the high cost barrier slows down widespread adoption. Addressing affordability and expanding reimbursement coverage will be essential for accelerating market growth across the region.

Limited Awareness and Availability in Emerging Healthcare Centers

Another major challenge in the Europe HIFU market is limited awareness and availability, particularly in smaller hospitals and emerging healthcare centers. While major urban hospitals in countries like Germany, France, and the UK have adopted HIFU technology, many regional and rural healthcare facilities still lack access to such advanced systems. This creates a gap in treatment availability and restricts patient access to non-invasive options. Additionally, awareness among both patients and some healthcare professionals remains relatively low compared to traditional treatment methods such as surgery or radiotherapy. Many physicians are still more familiar with conventional approaches, leading to slower adoption of HIFU in routine clinical practice. Limited training programs and lack of standardized treatment guidelines further contribute to this challenge. As a result, despite its effectiveness, HIFU adoption is uneven across Europe. Expanding education, training, and infrastructure development will be crucial to overcoming these limitations and ensuring broader market penetration.

Europe High-Intensity Focused Ultrasound Market

The Europe High-Intensity Focused Ultrasound (HIFU) market is expanding rapidly due to continuous technological innovation, strong healthcare systems, and rising demand for non-invasive medical procedures. Countries such as Germany, the United Kingdom, and France are heavily investing in upgrading HIFU infrastructure across both public hospitals and private healthcare facilities. The technology is increasingly being applied in oncology, gynecology, and aesthetic medicine, broadening its clinical scope across the region. Growing regulatory approvals, along with ongoing clinical trials, are accelerating market acceptance and integration into mainstream healthcare. In addition, increasing awareness among patients and physicians regarding the benefits of non-surgical treatments-such as reduced recovery time, minimal complications, and improved precision-is further boosting adoption. European healthcare systems, which emphasize cost-effectiveness and patient safety, are actively encouraging the use of advanced therapeutic technologies like HIFU. As a result, the market is expected to witness sustained growth driven by innovation and expanding medical applications.

Europe MRI HIFU Market

MRI-guided High-Intensity Focused Ultrasound (MRI-HIFU) is gaining significant traction across Europe due to its superior imaging precision and non-ionizing nature. This advanced modality allows real-time visualization of treatment areas, enabling highly accurate targeting of diseased tissues while preserving surrounding healthy structures. It is increasingly used for treating uterine fibroids, prostate disorders, and bone metastases with improved clinical outcomes. European hospitals and specialized medical centers are progressively integrating MRI-HIFU systems into oncology and gynecology departments to enhance treatment precision. Growth in this segment is strongly supported by government healthcare funding, research grants, and collaborations between medical imaging companies and device manufacturers. Continuous advancements in MRI technology and ultrasound integration are further improving procedural efficiency and safety. As healthcare providers prioritize minimally invasive and image-guided therapies, MRI-HIFU is becoming a key component of advanced treatment protocols across Europe's modern healthcare infrastructure.

Europe Prostate Cancer High-Intensity Focused Ultrasound Market

HIFU has emerged as an increasingly preferred treatment option for localized prostate cancer across Europe due to its non-invasive nature and high precision. The technology enables targeted destruction of cancerous tissues while preserving surrounding healthy organs, significantly reducing side effects compared to conventional surgery or radiation therapy. Countries such as Germany and the United Kingdom are leading adoption, supported by strong clinical outcomes and rising awareness among healthcare professionals and patients. Urology departments in major hospitals are increasingly incorporating HIFU as part of standard treatment offerings for early-stage prostate cancer. Positive clinical evidence demonstrating improved recovery times and reduced complications is further driving acceptance. Additionally, growing demand for outpatient-based cancer treatments is supporting market expansion. As healthcare systems continue to prioritize patient-centered and less invasive therapies, HIFU is expected to play a more prominent role in prostate cancer management across Europe.

Europe Aesthetics High-Intensity Focused Ultrasound Market

The use of HIFU in Europe's aesthetics industry is expanding steadily, driven by increasing consumer preference for non-surgical cosmetic procedures. HIFU is widely used for skin tightening, wrinkle reduction, and facial contouring, offering visible results without the need for invasive surgery or extended recovery periods. European consumers are increasingly seeking safe, effective, and natural-looking cosmetic enhancements, which is boosting demand for HIFU-based treatments. Clinics in countries such as France, Italy, and the United Kingdom are actively adopting this technology to expand their non-invasive treatment portfolios. The growing influence of social media and rising awareness of anti-aging treatments are also contributing to market growth. Additionally, advancements in device precision and safety have improved treatment outcomes, making HIFU more appealing to both practitioners and patients. As demand for aesthetic enhancement continues to rise, this segment is expected to experience sustained growth across Europe's beauty and wellness industry.

Europe High-Intensity Focused Ultrasound Hospitals Market

Hospitals across Europe are among the primary adopters of HIFU technology, particularly in oncology, gynecology, and urology applications. Leading medical institutions are integrating HIFU systems into surgical and treatment units to offer advanced non-invasive therapeutic options. The technology is increasingly valued for its ability to reduce surgical risks, shorten hospital stays, and improve patient outcomes. Hospitals in countries with well-developed public healthcare systems are at the forefront of adoption. Training programs, professional workshops, and partnerships with medical device manufacturers are further facilitating implementation. In addition, healthcare providers are investing in modernizing infrastructure to include advanced image-guided treatment technologies like HIFU. As hospitals aim to enhance service quality and efficiency while controlling healthcare costs, the adoption of HIFU is expected to increase steadily. This positions hospitals as a key growth engine in the European HIFU market landscape.

Europe High-Intensity Focused Ultrasound Research Centers Market

Research institutions across Europe play a critical role in advancing HIFU technology through innovation, clinical trials, and interdisciplinary collaboration. Universities and specialized hospitals are actively engaged in evaluating new clinical applications, optimizing treatment protocols, and validating long-term safety and efficacy. Countries such as France, Germany, and the Netherlands are major hubs for HIFU research, supported by strong government funding and private sector investments. Collaborative projects between academia, healthcare institutions, and medical device companies are accelerating technological development and expanding clinical indications. These research efforts are essential for transitioning HIFU from experimental use to widespread clinical adoption. Continuous innovation in imaging guidance, energy delivery systems, and treatment precision is further enhancing the technology's capabilities. As Europe continues to emphasize medical research and innovation, research centers will remain central to the long-term growth and evolution of the HIFU market.

France High-Intensity Focused Ultrasound Market

France is a leading market for HIFU in Europe, supported by a strong healthcare system and a research-driven medical environment. French hospitals are actively utilizing HIFU for cancer treatment, uterine fibroids, and aesthetic procedures. The country's commitment to clinical research and government support for advanced medical technologies has strengthened its position in the European HIFU landscape. A notable development includes EDAP initiating a clinical trial in February 2025 for pancreatic cancer treatment using HIFU technology, reflecting France's focus on expanding therapeutic applications. The trial, known as PULS, aims to evaluate both safety and effectiveness in phased clinical studies. Growing participation in global clinical research and increasing adoption in hospitals further enhance market development. With strong collaboration between healthcare institutions and medical technology companies, France continues to serve as a key innovation hub for HIFU advancement in Europe.

Germany High-Intensity Focused Ultrasound Market

Germany leads HIFU adoption in Europe due to its advanced healthcare infrastructure and strong emphasis on precision medicine. Hospitals across the country are widely implementing HIFU for treating prostate cancer, liver tumors, and aesthetic conditions. The integration of cutting-edge medical technology with strong clinical expertise supports widespread adoption. Collaboration between universities and medical device manufacturers continues to drive innovation and improve treatment outcomes. In April 2024, Insightec received CE clearance for Exablate Prime, an advanced HIFU system designed to enhance accuracy and procedural efficiency. This development reflects Germany's leadership in adopting next-generation medical technologies. High levels of healthcare funding and strong regulatory support further contribute to market expansion. As demand for minimally invasive treatments grows, Germany is expected to remain a key driver of innovation and adoption in the

European HIFU market.

United Kingdom High-Intensity Focused Ultrasound Market

The United Kingdom HIFU market is expanding steadily, supported by increasing adoption across both public and private healthcare sectors. NHS hospitals are incorporating HIFU for cancer and fibroid treatments, driven by strong clinical evidence and growing patient preference for non-invasive procedures. Private clinics are also contributing to market growth by offering aesthetic applications such as non-surgical facelifts and skin tightening. Government support for innovative healthcare technologies is further encouraging adoption. In January 2023, the UK Focused Ultrasound Foundation was launched to promote awareness, research, and clinical adoption of focused ultrasound technologies. This initiative aims to expand treatment accessibility and accelerate innovation in the field. With rising investment in healthcare modernization and growing awareness of advanced treatment options, the UK is expected to remain a significant contributor to Europe's HIFU market growth in the coming years.

Europe HIFU Market Segmentation

Imaging Technology

• Ultrasound HIFU Therapy
• MRI HIFU Therapy

Application

• Prostate Cancer
• Uterine Fibroids
• Neurological Disorders
• Aesthetics
• Others

End User

• Diagnostic Centers
• Hospitals
• Research Centers
• Others

Companies

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

Companies have been covered from 5 viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Koninklijke Philips N.V.
• EDAP TMS S.A
• Johnson & Johnson
• Medtronic Plc.
• Hitachi Ltd.
• Theraclion
• Stryker
• General Electrics